FDA Phases Out Fast Track Drug Reviews As Psychedelic Research Grants Surge

RecentNews.uk

The US FDA is reportedly ending its expedited drug review program.

Compass Pathways has submitted an application for psilocybin.

US federal authorities have committed $25 million to ibogaine research.

The shifts signal a complex changing environment for psychedelic medicine.

Should psychedelic-backed therapies be given expedited regulatory review?

Tap below to vote and see what others think.